Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tien-Hsien liquid (THL) is a traditional Chinese medicine (TCM) herbal mixture marketed as a dietary supplement for cancer patients. It is composed of several herbal extracts and has been studied for its potential anticancer and immunomodulatory properties. Research indicates that THL induces apoptosis in various human cancer cell lines through the activation of the caspase cascade (caspase-3, -8, and -9) while sparing normal cells. In clinical settings, a specific formulation known as Tien-Hsien Liquid Practical (THL-P) has been evaluated in Phase IIa trials for refractory metastatic breast cancer, where it demonstrated improvements in quality of life and immune function (increasing CD3, CD4/CD8, and NK cell counts) with a favorable safety profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tien-Hsien liquid.